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Introduction
Long-chain fatty acids (LCFAs) provide cellular energy and are pre-
cursors for membrane components and intracellular lipid stores. 
Their bioactive derivatives influence gene expression and signal 
transduction pathways. Distribution of LCFAs among organs, espe-
cially muscle, adipose tissue, and liver, is key to maintaining meta-
bolic homeostasis (1). In the bloodstream, LCFAs circulate as unes-
terified free fatty acids (FFAs) bound to albumin or as triglyceride 
(TG) and phospholipid components of lipoproteins. Tissue uptake of 
LCFAs requires transfer across an endothelial cell (EC) barrier, but 
the molecular events necessary for this remain unknown.
In cultured parenchymal cells, LCFA uptake occurs via a sat-
urable receptor-mediated pathway and a nonsaturable pathway 
thought to reflect passive diffusion (2, 3). Several proteins have 
been implicated in facilitating LCFA accumulation, including 
enzymes involved in FA acylation and the scavenger receptor clus-
ter of differentiation 36 (CD36) (4). CD36 (also called SR-B2) is 
a multifunctional protein involved in apoptotic cell uptake, signal 
transduction, cellular adhesion, angiogenesis, and immune func-
tion (5). It was first linked to lipid metabolism when it was shown 
to function as a macrophage receptor for oxidized LDL (6) and as 
an adipocyte receptor/transporter for LCFAs (7). LCFA binding 
to the CD36 ectodomain is followed by FA transfer to the plasma 
membrane through an internal tunnel that runs the length of the 
protein, as shown by the crystal structure of the CD36-LCFA com-
plex (8). CD36 also functions as a LCFA sensor, influencing activa-
tion of PPARs (9) and AMPK (10).
In mice, germline CD36 deficiency reduces acute accumulation of 
LCFAs in the heart, skeletal muscle, and adipose tissues (11). Moreover, 
Cd36–/– mice have increased fasting levels of FFAs (11, 12) and delayed 
clearance of postprandial lipids (11–13). The defect in LCFA uptake is 
also observed in CD36-deficient humans (14). Furthermore, a common 
haplotype at the CD36 locus is associated with greater circulating FFA 
levels (15). Whether the defect in FA uptake is consequent to reduced 
CD36 expression in ECs, parenchymal cells, or both is unknown. We 
bred mice with CD36 deletion specific to ECs (EC-Cd36–/–) or cardio-
myocytes (CM-Cd36–/–) to determine which cell type(s) regulate organ/
tissue accumulation of LCFAs and TGs. Our data show that EC CD36 is 
needed for optimal movement of LCFAs from the circulation to cardio-
myocytes (CMs). LCFA uptake was also diminished in brown adipose 
tissue (BAT) and skeletal muscle, but not liver, of EC-Cd36–/– mice. 
Loss of EC CD36 improved glucose tolerance and insulin sensitivity 
and increased glucose uptake during fasting in heart, skeletal muscle, 
and white adipose tissue (WAT). The data reveal that CD36-mediated 
FA transport across ECs limits tissue FA uptake and that its loss leads to 
metabolic effects in parenchymal cells.
Results
CD36 is abundantly expressed in vascular ECs and CMs in human 
and mouse hearts. We investigated CD36 distribution in human 
and mouse heart tissues and assessed the fidelity of our cell-spe-
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heart tissues with CD36 and the EC marker CD31. Both CD36 and 
CD31 colocalized to capillary ECs of Cd36fl/fl control mice, while 
CD36 protein was undetected in CD31-positive EC-Cd36–/– heart 
tissues (Figure 2B). We further confirmed the specificity of the 
EC versus CM deletions by immunofluorescence of isolated ECs 
and CMs from lung and heart tissues. We found that CMs from 
EC-Cd36–/– hearts contained normal levels of CD36 protein, 
whereas CD36 was undetectable in CM-Cd36–/– heart CMs (Figure 
2C). Primary ECs isolated from the lungs of Cd36fl/fl and inducible 
VE-cadherin Cd36–/–  mice (16) were stained for both VE-cad-
herin, an endothelium-specific molecule, and CD36 and showed 
an absence of CD36 staining in VE-cadherin–positive ECs from 
EC-Cd36–/– mice (Figure 2D).
To verify that Cd36 EC deletion did not cause off-target effects, 
we confirmed the presence of CD36 in CMs isolated from EC-Cd36–/– 
mice and analyzed the cells by Western blotting and quantitative 
real-time PCR (qRT-PCR) (Supplemental Figure 1G). These data 
proved that CD36 was deleted in ECs but not parenchymal cells.
To determine whether CD36 deletion modified the metabolic 
gene profile in ECs, we isolated ECs from Cd36fl/fl, EC-Cd36–/–, and 
CM-Cd36–/– mouse hearts using FACS. Genes involved in glucose 
metabolism were not altered significantly in ECs from the 3 groups 
(Supplemental Figure 1H). We also found no changes in FA oxida-
tion genes in ECs with CD36 deletion, consistent with glucose being 
the primary substrate for ATP production in these cells. Thus, CD36 
is not a major regulator of lipid or glucose metabolism in ECs.
We used laser capture microdissection (LCM) technology 
to isolate CMs and determine the expression of glucose and FA 
metabolism genes. Glut1 mRNA increased, while pyruvate dehy-
drogenase kinase 4 (Pdk4) and carnitine palmitoyl transferase 1 
(Cpt1) were decreased in the EC-Cd36–/– CMs (Supplemental Fig-
ure 1I). These changes suggest a switch from FA to glucose use.
CD36 deletion in ECs increases plasma FFA and postprandial TG 
levels, while decreasing plasma glucose levels and enhancing insulin sen-
sitivity. Deletion of EC Cd36 increased fasting plasma FFAs (Fig-
ure 3A), a phenotype similar to that of mice with global CD36 dele-
tion (12). Fasting plasma total cholesterol (TC), TGs, glycerol, and 
lipoprotein lipids (Supplemental Figure 2, A–E) were unchanged 
in 4-month-old male EC-Cd36–/– mice compared with levels in 
Cd36fl/fl controls. However, age-matched female EC-Cd36–/– mice 
showed decreased plasma glucose together with increased fasting 
plasma TC, FFA, and TGs associated with an increase in VLDL-TG 
and HDL-TC (Supplemental Figure 3, A–F). These sex differences 
in lipid levels might reflect previously reported sex differences in 
the regulation of tissue CD36 expression and muscle FA metabo-
lism (17, 18). We found that loss of CD36 in CMs did not alter circu-
lating levels of FFAs or glucose (Figure 3, A and B). Therefore, loss 
of CD36 only in ECs reproduced many of the overall metabolic 
effects seen with total-body CD36 KO.
Postprandial TG levels in response to fat intake were higher in 
EC-Cd36–/– mice. Plasma TG levels 2, 4, and 6 hours after olive oil 
gavage were higher in EC-Cd36–/– mice than in Cd36fl/fl mice (Fig-
ure 3C). We detected a greater than 2-fold increase in the AUC for 
TG clearance (AUCTG) in EC-Cd36–/– mice (Figure 3C), suggesting 
that EC CD36 is involved in the rapid clearance of circulating TGs. 
In contrast, loss of CM CD36 did not alter TG excursion (Figure 
3C). Slower postprandial TG clearance is characteristic of total 
cific deletions. We found that CD36 was present in ECs and CMs 
in both human and mouse hearts (Figure 1A) and that staining was 
most intense in small blood vessels, weaker in larger arteries, and 
absent in total Cd36–/– mouse hearts. In WT mouse hearts subjected 
to Langendorff perfusion and subsequent suborgan fractionation 
using gradient density separation and FACS, we found that Cd36 
mRNA levels were significantly higher in ECs than in CMs from 
both male (Figure 1B) and female mice (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI99315DS1). ISH data showed Cd36 mRNA 
expression in WT, but not total Cd36–/–, mouse hearts, with the most 
intense signals detected in capillary ECs (Supplemental Figure 1B).
CD36 mRNA and protein are specifically reduced in EC- and 
CM-Cd36–/– mouse hearts. To determine the contribution of EC 
versus CM CD36 to heart FFA uptake, we created a Cd36fl/fl mouse 
line (Figure 1C). We crossed Cd36fl/fl mice with Tie2-Cre mice to 
generate EC-Cd36–/– mice and with MHC-Cre mice to generate 
CM-Cd36–/– mice. Both groups were fertile and appeared normal. 
We used PCR to detect Cd36fl/fl and Cd36–/– alleles from tail (Fig-
ure 1D) and heart (Figure 1E) DNA. PCR product sequencing from 
Cd36-null fragments showed ablation of exons 3 and 4 of the Cd36 
gene after Cre-mediated recombination (Figure 1F). Cd36 mRNA 
and protein levels were reduced by more than 50% in the hearts 
of EC-Cd36–/– mice compared with levels in Cd36fl/fl mouse hearts; 
CM-Cd36–/– mice also had an approximately 50% reduction of 
Cd36 mRNA in the heart, with parallel reductions in protein con-
tent (Figure 1G). The approximately 50% reduction with either the 
EC or CM KO suggests that total heart CD36 is equally divided in 
these 2 cell types. EC-Cd36–/– mice had reduced Cd36 mRNA in 
skeletal muscle, BAT, and liver (Supplemental Figure 1, C–E), and 
we measured parallel reductions in CD36 protein in skeletal mus-
cle, adipose tissue (WAT and BAT), and liver (Figure 1H). Immu-
nohistologic analysis of cardiac ventricular sections stained with 
polyclonal rabbit CD36 antibody confirmed CD36 ablation spec-
ificity to capillary ECs from EC-Cd36–/– mice (Figure 2A). These 
mice had significantly reduced Cd36 levels in the lungs, which are 
particularly rich in ECs (Supplemental Figure 1F). To verify that 
CD36 is specifically deleted in ECs, we double stained EC-Cd36–/– 
Figure 1. CD36 distribution in human and mouse hearts and creation of 
EC- and CM-Cd36–/– mice. (A) CD36 antibody staining of CMs and blood 
vessel ECs from human and mouse hearts. Original magnification, ×20. (B) 
Male mouse heart suborgan fractionation showing Cd36 mRNA levels in 
different cell types (n = 12–18). Data represent mean ratios normalized to 
CM-Cd36–/– (set at 1.0). (C) Genomic structure of murine Cd36, the targeting 
vector, and the mutated allele. Gray boxes represent the numbered murine 
Cd36 exons. Red arrows indicate transcription orientation. Black bent 
arrows indicate the translation start site. PCR primers (blue arrows) were 
chosen to differentiate between the WT genomic allele and the homol-
ogously recombined allele. (D) PCR of tail genomic DNA (using primer 
1) and (E) heart tissue DNA (using primer 2) from Cd36fl/fl, EC-Cd36–/–, 
and CM-Cd36–/– mice. (F) PCR product sequencing showing ablation of 
exons 3 and 4 of Cd36 gene after Cre-mediated recombination. (G) Heart 
Cd36 mRNA in EC-Cd36–/– and CM-Cd36–/– mice quantified by qRT-PCR 
using primer 3 (n = 5–6, mean ± SD). Data are corrected for 18S rRNA and 
normalized to Cd36fl/fl controls. Immunoblots show CD36 in EC-Cd36–/– and 
CM-Cd36–/– mouse hearts. (H) Immunoblots of CD36 in EC-Cd36–/– muscle, 
WAT, BAT, and liver. *P < 0.05, #P < 0.01 and §P < 0.001 compared with 
Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 3 2 jci.org   Volume 128   Number 10   October 2018
(HFD-fed) mice. EC CD36 deletion did not change BWs com-
pared with those of controls (Figure 4A). As with chow, HFD-fed 
EC-Cd36–/– mice had higher circulating FFA levels (Figure 4B). 
These mice also had higher plasma TC and TG levels (Figure 4, 
C and D) due to increases in both LDL and HDL cholesterol (Sup-
plemental Figure 5C). Total-body Cd36–/– mice fed a HFD had 
improved insulin sensitivity (20). HFD-fed EC-Cd36–/– mice had 
lower glucose and insulin concentrations (Figure 4, E and F) and 
improved OGTTs (Figure 4G) and ITTs (Figure 4H). Because 
we had seen such prominent changes in gene expression in the 
heart, we assessed insulin signaling after a fasting/feeding epi-
sode. After fasting and refeeding, EC-Cd36–/– hearts had greatly 
increased phosphorylation of AKT and the ribosomal protein S6 
at S240/244, both of which are downstream targets of insulin 
signaling (Figures 4I), whereas heart insulin receptor (IR) phos-
phorylation did not change. To further assess insulin sensitivity, 
we obtained muscle, liver, and WAT from mice after insulin injec-
tion. In EC-Cd36–/– liver, we found that phosphorylated IR (p-IR) 
was significantly increased (Figure 4J). Deletion of Cd36 in ECs 
did not change IR, AKT, or S6 protein levels in skeletal muscle 
or WAT (Figure 4K and Supplemental Figure 5D). To test wheth-
er improved insulin sensitivity in HFD-fed EC-Cd36–/– mice was 
CD36 deficiency in mice (13) and humans (19) and may reflect 
greater product inhibition of lipoprotein lipase (LpL) by FFAs.
Glucose levels and insulin sensitivity are altered by loss of CD36 
in ECs. EC-Cd36–/– mice had decreased 16-hour fasting glucose 
levels and an improved oral glucose tolerance test (OGTT) (Fig-
ure 3D), as was previously found in total Cd36 KOs (20). The AUC 
for OGTT (AUCOGTT) for EC-Cd36–/– mice was 24% lower than for 
Cd36fl/fl mice (Figure 3D). Insulin tolerance tests (ITTs) in 2-hour–
fasted mice showed that the more rapid glucose removal was due 
to greater insulin sensitivity (Figure 3E).
We generated a second endothelial KO line by crossing Cd36fl/fl 
mice with VE-cadherin-Cre (VE-Cd36–/–) mice. In this model, plas-
ma glucose levels were decreased, while FFAs were increased, sim-
ilar to the effects seen in Tie2-Cre EC-Cd36–/– mice (Supplemental 
Figure 4, A and B).
To confirm that the changes in FFA and glucose levels were not 
due to off-target CD36 deletion, we created myeloid CD36-KO mice 
using the LysM-Cre transgene. The deletion did not reduce glucose 
or increase circulating FFA levels (Supplemental Figure 5, A and B).
CD36 deletion in ECs improves glucose homeostasis and insulin 
sensitivity in high-fat diet–fed mice. We next determined wheth-
er EC-CD36 loss affected FFAs and glucose in high-fat diet–fed 
Figure 2. Immunocytochemistry and immunofluorescence staining of heart tissue and isolated ECs and CMs. (A) CD36 staining of heart tissue from 
Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (top) and higher-magnification images of CD36 staining of vascular endothelium and CMs (bottom). Original 
magnification, ×40 (top) and ×400 (bottom). (B) Cd36fl/fl and EC-Cd36–/– heart sections were double stained with anti-CD31 (green) and anti-CD36 (red) 
antibodies. Scale bars: 5 μm. (C) Isolated CMs from Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mouse hearts stained with anti-CD36 antibody. Scale bars: 25 μm. 
(D) Isolated ECs from Cd36fl/fl and EC-Cd36–/– mice stained with anti–VE-cadherin (green) and anti-CD36 (red) antibodies. Original magnification, ×60.
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of significant changes in skeletal muscle uptake in the female mice 
are consistent with the known sex differences in skeletal muscle 
lipid metabolism (21). The signal in WAT was low, and uptake dif-
ferences were not significant. Hexanoic acid plasma removal and 
uptake into tissues were similar in mice of all 3 genotypes (Figure 
5, C and D). These data show that EC-CD36 is required for optimal 
LCFA uptake by the heart, skeletal muscle, and BAT.
We also assessed acute LCFA accumulation in the heart and 
other tissues in real time using [11C]palmitate PET. As found with 
radiolabeled tracers, EC-Cd36–/– mouse hearts had a marked 
reduction in tracer uptake compared with Cd36fl/fl and CM-Cd36–/– 
mouse hearts (Figure 5E). We also detected significantly reduced 
FA uptake by skeletal muscle and BAT in EC-Cd36–/– mice (Figure 
5F). In contrast to the reduction noted with EC deletion, neither 
[3H]oleic acid (Figure 5B) nor PET scan assessment of heart pal-
mitate uptake (Figure 5E, right) in CM-Cd36–/– mice differed from 
what was observed in Cd36fl/fl mice. Neither deletion affected pal-
mitate uptake into the liver (Supplemental Figure 6C).
CD36 deletion in ECs increases glucose uptake by heart, skel-
etal muscle, and BAT. Fasting reduces glucose uptake by heart 
and muscle, an adaptation impaired by total CD36 deficiency in 
humans (22) and mice (4, 9). We examined tissue uptake of [18F]
related to reduced ceramides and diacylglycerols (DAGs), we 
assessed the distribution of these lipids in skeletal muscle and 
heart. Long-chain ceramides (Cer18:1) in the heart and very long-
chain ceramides (Cer22:0, Cer24:0, and Cer24:1) in both heart 
and skeletal muscle were significantly reduced in EC-Cd36–/– mice 
(Figure 4, L and M). Cardiac and muscular DAGs were not altered 
(Supplemental Figure 5, E and F). Thus, EC-CD36 deletion pro-
tected mice from HFD-induced insulin resistance and was associ-
ated with reduced ceramide species.
CD36 deletion in ECs reduces LCFA uptake by heart, skeletal mus-
cle, and BAT. To test directly whether loss of CD36 in ECs reduces 
the uptake of LCFAs in vivo, we injected [3H]oleic acid and [14C]
hexanoic acid, which is not recognized by CD36, into 16-hour–
fasted male mice and assessed their tissue uptake. Compared with 
Cd36fl/fl and CM-Cd36–/– mice, we observed that EC-Cd36–/– mice 
had significantly delayed plasma clearance of oleic acid (Figure 
5A) and a greater than 50% reduction in oleate uptake by heart, 
quadriceps muscle, and BAT (Figure 5B). In contrast, uptake 
by liver, lung, and kidney was unchanged. We observed similar 
results of reduced plasma LCFA clearance and uptake into heart 
and BAT in female mice (Supplemental Figure 6, A and B). Howev-
er, skeletal muscle uptake was not altered in female mice. The lack 
Figure 3. EC-Cd36–/– mice have increased FFA and postprandial TG levels but improved glucose metabolism. (A) Plasma FFAs in 4-month-old male 
mice fasted for 16 hours (n = 6–8). (B) Plasma glucose levels (n = 6–7) in Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice. (C) Postprandial TG response in Cd36fl/fl, 
EC-Cd36–/–, and CM-Cd36–/– mice. Plasma TG concentrations were measured 0, 2, 4, and 6 hours after intragastric administration of olive oil (n = 5–7). Also 
shown is the AUC for postprandial TG levels. (D) Four-month-old male mice (n = 4–8) were fasted for 16 hours before oral glucose administration. Tail blood 
was collected for glucose measurements at 0, 15, 30, 60, and 120 minutes after glucose administration. Also shown is the AUC of glucose excursions. (E) 
For ITTs, mice were fasted for 4 hours and given 0.75 U/kg BW insulin i.p. Tail blood samples were obtained before insulin administration (t0) and then 15, 
30, 45, 60, and 120 minutes after insulin injection (n = 4–5 mice; data are representative of 2 independent experiments). Data represent the mean ± SD.  
*P < 0.05, #P < 0.01, and §P < 0.001 compared with Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.
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deoxyglucose (FDG]DG) using PET in 16-hour–fasted mice and 
found that glucose uptake increased in heart, muscle, and WAT of 
EC-Cd36–/– mice compared with controls (Figure 5G). In contrast, 
tissues of CM-Cd36–/– mice showed no changes in glucose uptake 
(Supplemental Figure 6D). These data show that EC CD36 regu-
lates the fasting-induced metabolic shift by tissues, which spares 
glucose use and increases reliance on FAs.
CD36 deletion in either ECs or CMs reduces heart lipid storage. 
The heart normally increases its lipid stores during fasting. Stud-
ies in Cd36–/– mice suggest that CD36 is required for this adapta-
tion (4, 9, 10, 23). We fasted mice for 16 hours and assessed lip-
id droplet accumulation using BODIPY dye. We found that lipid 
droplet accumulation was significantly reduced in EC-Cd36–/– 
hearts (Figure 6A). Lipid droplet numbers were significantly 
decreased in both EC-Cd36–/– and CM-Cd36–/– hearts, as assessed 
by electron microscopy (Figure 6, B and C), while heart mor-
phology appeared normal. Direct measurements of heart TGs 
showed that hearts from EC-Cd36–/– mice had a 49% reduction 
in TGs and CM-Cd36–/– mice had a 53% reduction (Figure 6D). 
Thus, CD36 deletion in either ECs or CMs reduced heart lipid 
accumulation. We also observed decreased cardiac lipid accu-
mulation in VE-Cd36–/– mice (Supplemental Figure 7, A and B). 
As might be expected with reduced lipid uptake into peripheral 
tissues, EC-Cd36–/– mice had increased liver TG content (Supple-
Figure 4. EC-Cd36–/– improves glucose homeostasis and increases insulin sensitivity in 6-month-old male mice fed a HFD for 4 months. (A–E) BW, plas-
ma lipids, and glucose after a 16-hour fast. (F) Plasma insulin after a 16-hour fast followed by a 4-hour refeeding period. P value was determined by 1-way 
ANOVA. (G) For GTTs, male mice fasted for 16 hours were given oral glucose, and tail blood samples were collected for glucose measurements at 0, 15, 30, 
60, and 120 minutes. Also shown is the AUC of glucose excursions. (H) For ITTs, mice fasted for 4 hours were given 0.75 U/kg BW insulin i.p. Tail blood 
samples were obtained at t0 and then 15, 30, 45, 60 and 120 minutes after insulin administration. (I) Activity of IR, AKT, and S6 in Cd36fl/fl and EC-Cd36–/– 
mice 20 minutes after insulin injection, with densitometric analysis of (I) heart, (J) liver, and (K) skeletal muscle tissue. (L and M) Individual ceramide (Cer) 
species in heart (n = 5) and muscle (n = 9–10). Data represent the mean ± SD. *P < 0.05 and #P < 0.01 compared with Cd36fl/fl controls; 1-way ANOVA with 
Dunnett’s multiple comparisons test (A–E and G–M).
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 3 3 5jci.org   Volume 128   Number 10   October 2018
mental Figure 7C). The increase in heart TGs was associated with 
an increase in diacylglycerol acyl transferase 1 (DGAT1) (Supple-
mental Figure 1E), a compensation that might have prevented the 
accumulation of lipids that interfere with insulin signaling (24, 25).
EC or CM CD36 deletion reduces the expression of FA metabo-
lism heart genes and differentially alters glucose metabolism genes. 
We performed RNA sequencing (RNA-seq) to gain an unbiased 
global view of transcript expression in EC-Cd36–/– and CM-Cd36–/– 
mouse hearts. Gene heatmap analysis (Figure 7) showed marked 
expression changes in hearts from both groups of mice. Expres-
sion of glucose metabolism and glucose signaling genes showed 
differential regulation. In EC-Cd36–/– mouse hearts, we detected 
increases in mRNA levels of genes mediating glucose uptake and 
oxidation such as Slc2a1 (Glut1), Slc2a4 (Glut4), Pcx (pyruvate 
carboxylase), Hk2 (hexokinase 2), Gck (glucokinase), and Pfk-
fb2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2). 
Decreased expression of Pdk4 (pyruvate dehydrogenase kinase 4), 
which inhibits pyruvate conversion to acetyl-CoA, was consistent 
with enhanced glucose utilization. These changes were associated 
with increased expression of insulin signaling pathway genes such 
as Irs1 (insulin receptor substrate 1), Pten (phosphatase and tensin 
homolog), Pik3r1 (phosphoinositide 3 kinase regulatory subunit 1, 
also known as p85), Foxo1 (Fox protein 01), and Mapk4 (MAPK4).
In CM-Cd36–/– mice, in contrast to EC-Cd36–/– mice, we detect-
ed reduced cardiac expression of glucose metabolism genes, while 
expression of genes for insulin signaling was not affected. These 
data suggest that CD36 deletion in ECs enhances the expression 
of genes related to glucose utilization and insulin action, while the 
effect of the deletion in CMs is opposite or neutral.
PPARs, especially PPARα, modulate LCFA oxidation in the 
heart. Ppara mRNA levels increased in EC-Cd36–/– hearts (Figure 
7, red arrow), while levels of PPARγ and PPARβ, and PPARδ were 
unchanged in both EC- and CM-KO hearts. However, expres-
sion of FA metabolism genes including many PPARα targets was 
decreased in both groups of mice. For example, expression of 
Slc27a1 (FA transport protein 1), Cpt1a (carnitine palmitoyl trans-
ferase 1a), Cpt2, Acot2 (acyl CoA thioesterase 2), Acadl (acyl CoA 
hydrogenase 1), Acadm (medium chain ACAD), and Hsd17b4 
(hydroxysteroid 17 β dehydrogenase 4) decreased markedly in 
EC-Cd36–/– and CM-Cd36–/– hearts. In both groups, Slc25a20 (car-
nitine acyl carnitine translocase, also known as Cact), which medi-
ates the transport of acylcarnitines from the cytosol to the mito-
chondrial matrix, was reduced (Figure 7). These changes indicate 
that CD36 in both ECs and CMs regulates tissue FA metabolism. 
In CM-Cd36–/– hearts, these changes were consistent with the 
effects of CD36 on FA oxidation, as documented in an overexpres-
sion mouse model (26) and in tissue culture experiments (27).
Kyoto Encyclopedia of Genes and Genomes (KEGG) anal-
yses of insulin- and PPAR-activated pathways highlighted the 
enhanced insulin signaling detected in EC-Cd36–/– hearts, with 
increased expression of major regulators of GLUT4 translocation, 
lipogenesis, and glycogenesis (Figure 8A). This was not apparent 
in CM-Cd36–/– hearts. We noted diminished expression of major 
PPAR targets in EC-Cd36–/– hearts (Figure 8B). Expression levels 
Figure 5. EC-Cd36–/– mice have reduced tissue LCFA uptake during fasting. (A–D) Uptake of oleic and hexanoic acids in EC-Cd36–/– mice. Four-month-old 
mice were fasted for sixteen hours and given a tail i.v. injection of [3H]oleic acid and [14C]hexanoic acid. (A) Plasma 3H radioactivity in Cd36fl/fl, EC-Cd36–/–, and 
CM-Cd36–/– mice (n = 5–6) measured at the indicated time points after injection. Scale bars: 50 μm. (B) 3H content of different tissues, (C) plasma 14C radioactiv-
ity, and (D) 14C content of different tissues. (E) Real-time [11C]palmitic acid uptake into heart, and (F) tissue [11C]palmitic acid uptake in Cd36fl/fl and EC–Cd36–/– 
male mice (n = 4). (G) Tissue FDG uptake in Cd36fl/fl and EC–Cd36–/– mice (n = 4) derived from summing the uptake kinetics up to 60 minutes after tracer admin-
istration. Also shown are representative scans of FDG accumulation at 60 minutes in the hearts of control and EC-Cd36–/– 16-hour–fasted mice. Max, maximum. 
Data represent the mean ± SD. *P < 0.05, #P < 0.01, and §P < 0.001 compared with Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.
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CD36 and that EC-specific CD36 deletion reduces acute LCFA 
uptake into heart and other tissues. Moreover, EC-Cd36–/– mice 
have increased insulin sensitivity and lack myocardial lipid drop-
let accumulation with fasting. Reductions in ceramides might have 
contributed to the improved insulin sensitivity. The reduction of 
FA uptake into BAT might have important implications for thermo-
genesis. In this regard, Bartelt et al. (30) have shown that both LpL 
and CD36 affect BAT uptake of FAs during cold exposure.
Several reports have suggested that ECs are a major regulator 
of tissue LCFA metabolism. These reports did not directly investi-
gate EC CD36, but some included indirect evidence that is consis-
tent with our current findings. Deletion of EC PPARγ increased cir-
culating LCFAs (31) and reduced expression of several PPARγ gene 
targets in ECs, including CD36. Meox2/Tcf15 heterodimer tran-
scription factors (TFs) in ECs have been reported to regulate FA 
transfer across the cardiac capillary endothelium (32) and to affect 
the expression of FA-metabolizing genes, including Cd36. Dele-
tion of EC VEGF-B (33) was reported to cause changes in EC LCFA 
uptake as a result of transcriptional regulation of vascular-specific 
FA transport proteins 3 and 4, but this was not confirmed by others 
(34). A recent report showed that a metabolite of branch chain ami-
of several PPAR and insulin signaling pathway genes such as Pparα 
and Glut1 were increased in hearts of EC-Cd36–/– mice, while Fas 
and Ampk expression levels were decreased (Figure 8C). Hearts 
from CM-Cd36–/– mice, like those from germline Cd36–/– mice, had 
higher Ampk mRNA levels (Supplemental Figure 8A) (10, 23). This 
contrasted with lower Ampk levels in hearts from EC-Cd36–/– mice 
(Figure 8A), perhaps reflecting greater glucose uptake. However, like 
in EC-Cd36–/– hearts, we found that expression levels of major PPAR 
target genes in CM-Cd36–/– hearts were decreased (Supplemental 
Figure 8B). These data were confirmed by qRT-PCR (Figure 8C). We 
also observed decreased expression of Pdk4, Cpt1, and Aox mRNA in 
female EC-Cd36–/– mouse hearts (Supplemental Figure 8C).
Discussion
Delivery of LCFA to parenchymal cells in tissues that do not have 
fenestrated capillaries involves transfer from the circulation to 
parenchymal cells. This movement of LCFAs requires their transfer 
either through or around ECs. CD36 has been reported to mediate 
LFCA uptake into muscle and adipose tissues (11, 12) and LCFA 
accumulation in CMs (28) and other cells (29), but its role in ECs 
had not been directly studied. We show that ECs robustly express 
Figure 6. CD36 deletion in ECs or CMs reduces heart 
lipid storage during fasting. (A) Heart tissue sections 
from Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice were 
stained with BODIPY 493/503. Scale bars: 50 μm. (B) 
Electron micrographs (original magnification ×3,400, 
top row, and ×15,000, bottom row) of myocardial tissue 
showing a significant decrease in lipid droplets within 
the sarcoplasm of CMs from EC-Cd36–/– and CM-Cd36–/– 
mice. Yellow arrows indicate lipid droplets. (C) Lipid 
droplet numbers in heart tissue sections (n = 4) from 
Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (expressed 
per 100 μm2). (D) Heart TG content in Cd36fl/fl (n = 10), 
EC-Cd36–/– (n = 6), and CM-Cd36–/– mice (n = 3). Data 
represent the mean ± SD. *P < 0.05, #P < 0.01, and  
§P < 0.001 compared with Cd36fl/fl controls; 1-way  
ANOVA with Dunnett’s multiple comparisons test.
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on the cell surface and FA uptake by 
ECs and adipocytes (36).
Robust CD36 expression in capillary 
ECs (37) is found in tissues that are most 
active in circulating LCFA extraction 
and that also express LpL and its EC 
anchoring protein glycosylphosphatidy-
linositol-anchored high-density lipopro-
tein binding protein 1 (GPIHBP1). This 
expression pattern suggests that CD36 
is important in LCFA trafficking across 
smaller blood vessels and capillaries, 
where most nutrient uptake occurs. ECs 
are not major sites of FA oxidation, so 
CD36 in capillaries is likely to be more 
important for LCFA transport than for 
LCFA-derived ATP production. This 
conclusion is supported by our data 
showing that lack of CD36 expression 
does not change EC mRNA levels of FA 
or glucose metabolism genes.
The lack of lipid droplet accumu-
lation with EC and CM CD36 deletion 
shows that CD36 expression at both 
sites is required for optimal delivery 
of LCFAs to the heart. The defect in 
uptake into EC-Cd36–/– mouse hearts 
was evident using 2 types of tracer 
kinetic studies: radiolabeled LCFA and 
[11C]palmitate PET. Both of these tech-
niques assess the rapid accumulation 
of LCFAs and, for this reason, might 
have failed to show a defect in LCFA 
uptake into CM-Cd36–/– hearts; CM 
CD36 is well established as a media-
tor of LCFA accumulation in cultured 
CMs (38, 39) and as a provider of sub-
strates required for the response to 
acute afterload (40). In addition, our 
studies highlight important differenc-
es in the contribution of ECs versus 
CMs to FA metabolism in the heart, 
and additional studies are needed to 
understand the mechanisms underly-
ing these differences.
Loss of EC CD36 led to improved 
insulin action and glucose disposal, 
which we demonstrated using cardiac 
gene expression, OGTTs, and ITTs. 
These effects were confirmed in HFD-
fed mice. Improvements in OGTTs and 
ITTs were similar to those observed 
with PPARα (41) or GLUT4 deletion (42). In addition, circulating 
glucose levels were reduced, as was found with some (43), but not 
all (44), genetic mutations that reduce FA oxidation. FDG PET 
showed increased glucose uptake into heart, skeletal muscle, and 
WAT with EC CD36 deletion. CM-Cd36–/– mice did not have sim-
no acids modulated both LCFA movement across ECs and insulin 
sensitivity (35). Interestingly, the molecular mechanisms mediat-
ing FA uptake by EC CD36 might differ among tissues. Salameh 
et al. recently reported on a mechanism specific to adipocytes, 
describing a prohibitin–annexin A2 complex that increases CD36 
Figure 7. Heart tissue mRNA expression in mice with EC or CM CD36 deletion. Clustered heatmaps from 
RNA-seq data showing differential expression profiles for Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice. Red 
indicates overabundant expression; blue indicates underabundant expression.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 3 8 jci.org   Volume 128   Number 10   October 2018
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 3 3 9jci.org   Volume 128   Number 10   October 2018
er Cd36fl/fl mice were identified by tail genomic DNA analysis with 
primer 1F specific to the upstream LoxP locus (5′-ATTGGCATCT-
GTGTAGCGCTCTTGGC-3′) and primer 1R (5′-TGCTACTATG-
CACTCCATGCAGGC-3′), an antisense specific to the downstream 
LoxP locus. CD36 deletion in EC-Cd36–/– hearts was confirmed by 
PCR of heart tissue DNA and mRNA with primers 2 and 3 (Supple-
mental Table 1), respectively. Mice were maintained under a constant 
light-dark cycle (light from 7:00 am to 7:00 pm) and received either 
a standard diet (catalog 5053, LabDiet) or a HFD containing 65% fat 
(catalog D12492, Research Diets).
Human tissues. Normal human heart tissues were obtained from 
the Department of Surgery at Columbia University Medical Center.
Western blot analysis. Total proteins were obtained from fresh heart 
tissues of 4- to 6-month-old EC-Cd36–/– and CM-Cd36–/– mice and lit-
termate controls using a RIPA Kit (Santa Cruz Biotechnology). Proteins 
(30 μg), separated by Western blotting, were probed for CD36 (catalog 
AF2519, R&D Systems, 1:200 dilution) and α-tubulin (catalog ab7291, 
Abcam, 1:5,000 dilution) as a control. Antibodies against Akt (Ab 9272), 
p-Akt (S473) (mAb 4060), S6 (mAb 2217), p-S6 (S240/244) (Ab 2215), IR 
(mAb 3025), p-IR (mAb 3024), and β-actin (mAb 4970) were obtained 
from Cell Signaling Technology. Signals were quantified by densitome-
try using the Odyssey Fc Imaging System (LI-COR Biotechnology).
Heart and plasma lipids. Blood from fasted (4 or 16 h) mice was 
collected from the retro-orbital plexus. Plasma TC, TGs, and FFA were 
measured enzymatically using an Infinity Kit (Thermo Electron Corp.) 
and a NEFA C Kit (Wako). To measure heart TGs, hearts were perfused 
with PBS and homogenized at 4°C in 1 M NaCl buffer with lipase inhib-
itors. Lipids were extracted from heart tissues (50 mg) according to a 
modified Folch method (54). The dried lipids were solubilized in PBS 
with 2% Triton X-100, and TG levels were measured using an Infinity 
TG Kit (Thermo Electron, Thermo Fisher Scientific.).
IHC. Human and mouse cardiac ventricular specimens were 
fixed in 10% buffered formaldehyde and embedded in paraffin, and 
5-μm-thick microtomic sections were stained with a 1:100 dilution of 
mouse and human CD36 antibodies (AF2519, AF1955; R&D Systems). 
After washing, sections were incubated (2 h at room temperature) with 
a biotinylated rabbit anti-goat IgG antibody. Staining specificity was 
tested by omission of primary antibodies.
Immunofluorescence staining. Cardiac ventricular tissues from 
4-month-old male mice were embedded in Tissue-Tek OCT Com-
pound (Sakura). Frozen sections (5-μm thickness) were fixed in 10% 
formalin for 30 minutes, washed 3 times in PBS, and blocked for 1 hour 
in 1% BSA-PBS at room temperature. The fixed sections were incubat-
ed (2 h, room temperature) with a 1:100 dilution of either mouse CD36 
(catalog AF2519, R&D Systems) or CD31 (catalog 102514, BioLegend) 
antibody  followed by washing and incubations (1 h) with a secondary 
antibody (1 : 500 dilution) coupled to Alexa Fluor 488 or 594 (Invitro-
gen, Thermo Fisher Scientific). Washed sections were then stained with 
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientif-
ic), and digital images were obtained with a Leica confocal microscope. 
Isolated ECs were fixed with 4% PFA, permeabilized with 0.2% Triton 
X-100, and blocked with donkey serum. Then, cells were incubated 
with anti–VE-cadherin (ab33168, Abcam) and CD36 (AF2519, R&D 
Systems) antibodies followed by secondary antibodies conjugated with 
Alexa Fluor 488 and Alexa Fluor 594. Nuclei were visualized with DAPI. 
Imaging was performed using a Nikon Eclipse inverted microscope at 
×60 magnification.
ilar improvements in insulin action or glucose metabolism, and, 
instead, hearts from these mice had downregulated expression 
of some glucose uptake genes, opposite to what would be expect-
ed with reduced lipid uptake. These changes might reflect myo-
cyte-autonomous actions of CD36 that regulate insulin signaling 
(45). These separate effects on parenchymal biology could explain 
the propensity to develop insulin resistance in humans with CD36 
mutations (46).
In humans, CD36 deficiency has a prevalence of 0.3% to 
9%, with a higher incidence in Asian and African populations. 
Individuals with complete CD36 deficiency have higher serum 
levels of fasting TGs (47) and chylomicron remnants (19). These 
lipid abnormalities likely reflect defective tissue FA metabolism, 
as CD36-deficient individuals show markedly reduced LCFA 
uptake by the heart (14, 22) and have enhanced myocardial glu-
cose uptake (22).
In summary, our data show that ECs are major sites of reg-
ulation of LCFA uptake and, in turn, tissue lipid metabolism 
and insulin sensitivity. By regulating heart and skeletal muscle 
FA delivery and glucose utilization, EC CD36 is a major factor 
affecting tissue fuel selection and systemic metabolism. Whether 
EC CD36 actions are beneficial for normal or diseased hearts is 
uncertain (48–50) and probably depends on the physiologic sit-
uation. Reduction of LCFA uptake leads to impaired energy pro-
duction during fasting or exercise, but also protects against excess 
lipid accumulation (lipotoxicity) (51) and improve glucose utiliza-
tion during hypoxia (52). The vascular endothelium represents an 
important and accessible therapeutic target (53), and our findings 
suggest that targeting EC CD36 could be a means to influence tis-
sue FA uptake and prevent or treat a variety of diseases caused by 
abnormal lipid utilization. 
Methods
Generation of Cd36fl/fl mice. A Lox (L83) site and Frt-Neo-Frt-LoxP 
(FNFL) cassette were engineered to flank a 1.7-kb sequence with 
exons 3 and 4 of CD36 to generate a floxed/Neo CD36 allele on a 
bacterial artificial chromosome (BAC). A gene-targeting vector was 
created by retrieving the 2-kb short homology arm (5′ to L83), the 
floxed sequence containing exons 3 and 4, the FNFL cassette, and the 
10-kb-long homology arm (end of FNFL to 3′) into a plasmid vector 
carrying a diphtheria toxin α (DTA) chain negative selection marker. 
The FNFL cassette conferred G418 resistance during gene target-
ing in KV1 (129B6 hybrid) embryonic stem (ES) cells, and the DTA 
cassette provided autonomous negative selection to reduce random 
integration. Identified targeted ES cells were injected into C57BL/6 
blastocysts to generate chimeric mice. Male chimeras were bred 
with homozygous ACTB (Flpe/Flpe) C57BL/6 females to remove the 
neomycin cassette and transmit the floxed CD36 allele (Flpe recom-
binase). The mice were then crosLoxsed with Tie2-Cre and MHC-
Cre mice (C57BL/6) to generate EC-Cd36–/– and CM-Cd36–/– mice 
and with LysM-Cre mice to create myeloid cell deficiencies. Found-
Figure 8. KEGG analysis of insulin signaling and PPAR pathways. KEGG 
analysis of (A) insulin and (B) PPAR signaling pathways. (C) qRT-PCR 
analysis of heart mRNA in Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (n = 
5–7). Data are shown as the mean ± SD. *P < 0.05 compared with Cd36fl/fl 
controls; 1-way ANOVA with Dunnett’s multiple comparisons test.
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μg/ml) for an additional 10 minutes before the end of the incubation. 
Cells were pelleted, resuspended, filtered (70-μm Flowmi cell strain-
er), and sorted on a FACSAria Fusion (BD Biosciences). Singlet cells 
were gated by forward scatter area (FSC-A) and forward scatter height 
(FSC-H). Additional gating of live (calcein AM+7-AAD–) cells was per-
formed. CD45–CD31+ EC fractions were collected for RNA isolation.
ISH. CD36 mRNA expression was detected in frozen sections via 
ISH using probes and the QuantiGene ViewRNA tissue assay (Affyme-
trix) according to the manufacturer’s instructions. No probe controls 
or tissues from Cd36-KO mice were used for negative controls.
LCM. Mouse heart tissues were filled with OCT compound. Poly-
ethylene naphthalate (PEN) membrane glass slides were prepared 
for cryosectioning. The tissue block was cryosectioned entirely at 
10 μm and stained with H&E for histomorphologic identification of 
cardiomyocytes. A Leica DM6000 B microscope was used for car-
diomyocyte harvesting. Captured cardiomyocytes were subjected to 
RNA purification (ARCTURUS PicoPure RNA Isolation Kit, Applied 
Biosystems, Thermo Fisher Scientific) and cDNA amplification (The 
Ovation Pico WTA System V2, NuGEN).
Tissue gene expression. Four-month-old mice were fasted for six-
teen hours. Total RNA was prepared using a Pure Link Micro-to-Mi-
di Total Purification Kit (Invitrogen, Thermo Fisher Scientific). RNA 
(1 μg) was treated with DNase I (Invitrogen, Thermo Fisher Scientific) 
for 15 minutes and reverse transcribed using the ThermoScript 
RT-PCR Kit (Invitrogen, Thermo Fisher Scientific). An ABI 7700 sys-
tem (Applied Biosystems, Thermo Fisher Scientific) and SYBR Green 
PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific) 
were used for qRT-PCR. For analysis, we used Sequence Detection 
Software (Applied Biosystems, Thermo Fisher Scientific) and stan-
dard curves generated using undiluted and diluted (1:10, 1:100, and 
1:1,000) cDNA heart tissue samples. Correlation coefficients were 
0.98 or greater. Data were normalized to 18S rRNA.
RNA-seq data analysis. Raw sequencing data were received in 
FASTQ format. Read mapping used Tophat 2.0.9 against the mm10 
mouse reference genome. The resulting BAM alignment files were 
processed using the HTSeq 0.6.1 python framework and respective 
mm10 GTF gene annotation (UCSC database). The Bioconductor 
package DESeq2 (3.2) was used to identify differentially expressed 
genes (DEGs) and for statistical analysis based on a negative binomi-
al distribution model. The resulting values were adjusted using the 
Benjamini-Hochberg method for FDR determination. Genes with an 
adjusted P value of less than 0.05 were determined to be differentially 
expressed, and KEGG Analysis was performed to identify top canoni-
cal pathways being altered. RNA-seq data were deposited in the NCBI’s 
Gene Expression Omnibus (GEO) database (GEO GSE116350).
Electron microscopy. Left ventricles from 16-hour–fasted 4-month-
old male mice were fixed with 2.5% glutaraldehyde and 2% parafor-
maldehyde in 0.1M sodium cacodylate buffer (pH 7.2) for 2 hours and 
then postfixed with 1% osmium tetroxide (1.5 h at room temperature), 
processed, and embedded in EMbed 812 (Electron Microscopy Sci-
ences). Ultrathin sections (60-nm) were cut (Leica UC6 microtome), 
mounted onto 200 mesh copper grids, and stained with uranyl acetate 
and lead citrate. Stained grids were examined with a Philips CM-12 
electron microscope and photographed with a Gatan (4 k × 2.7 k) digi-
tal camera. Lipid droplets were counted in random 100-μm2 areas.
Uptake of [3H]oleic acid and [14C]hexanoic acid. Cd36fl/fl, EC-Cd36–/–, 
and CM-Cd36–/– mice (4-month-old, 16-hour–fasted) were injected i.v. 
Lipoprotein isolation. Plasma was pooled from EC-Cd36–/– mice 
fed chow or a HFD. Lipoprotein fractions were separated by a previ-
ously described method (55).
OGTT. Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice fasted for 16 
hours were given 2 g glucose/kg body mass intragastrically. Tail blood 
samples were collected and glucose measured 0, 15, 30, 60, and 120 
minutes after gavage.
Plasma insulin measurements. Cd36fl/fl and EC-Cd36–/– were fast-
ed for 16 hours and refed for 2 hours. Blood was collected from the 
retro-orbital plexus, and plasma insulin levels were measured using a 
mouse ultrasensitive insulin ELISA kit (ALPCO).
ITTs. Mice were fasted for 4 hours and then given human insulin 
(Eli Lilly, 0.75 U/kg BW) intraperitoneally. Tail blood was obtained 0, 
15, 30, 45, 60, and 120 minutes after insulin injection.
Insulin signaling test. For insulin-induced changes, 2 different meth-
ods were used to assess insulin signaling in 3-month-old male mice fed 
a HFD for 6 weeks using. Changes in the heart were most evident when 
assessed after fasting (16 h) followed by refeeding (2 h), after which 
hearts were harvested and used for Western blot analysis. Other tissues 
were studied after i.p. insulin injection (0.50 U/kg BW human insulin, Eli 
Lilly). Skeletal muscle, liver, and WAT were harvested 20 minutes after 
insulin injection and then used for Western blotting.
Lipid droplet staining. Cardiac ventricular tissues from 4-month-
old male mice were embedded in Tissue-Tek OCT Compound (Saku-
ra). Frozen sections of myocardium (5-μm thickness) were fixed in 10% 
formalin for 30 minutes at room temperature and then washed 3 times 
in PBS. The fixed sections were then incubated with 4 μM BODIPY 
493/503 dye (catalog D3922, Invitrogen, Thermo Fisher Scientific) for 
30 minutes at room temperature. After washing, sections were stained 
with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Sci-
entific) and covered with glass coverslips (VWR, Avantor). The digital 
images were obtained with a Leica confocal microscope.
Postprandial lipemia. After a 16-hour fast, mice maintained on a chow 
diet received an intragastric bolus of 0.3 ml olive oil. Tail blood samples 
were collected before and 2, 4, and 6 hours after gavage. Plasma TG con-
centration was assayed with an Infinity Kit (Thermo Fisher Scientific).
EC isolation. Lungs harvested from Cd36fl/fl and EC-Cd36–/– 
mice (Tie2-Cre) were minced and enzymatically digested in MACS 
C-tube (Miltenyi Biotec). Cells were centrifuged, resuspended in 
PEB buffer (1× PBS, 0.5% BSA, 2 mM EDTA), blocked with FcR 
blocking reagent (Miltenyi Biotec), and then incubated with CD31 
conjugated microbeads for 15 minutes at 4°C. The cell suspension 
was passed through a MACS separation column, the column was 
washed with PEB buffer (3×), and the cells eluted and plated onto 
gelatin-coated coverslips in 6-well plates.
Heart suborgan fractionation. Cardiac cells were dissociated as 
described previously using Liberase TH (0.125 U/ml) (Millipore Sigma) 
(56). The cell suspension was filtered through a 100-μm strainer and 
centrifuged at 50 g for 5 minutes. CMs were pelleted and subjected to 
Percoll density gradient centrifugation (1,200 g for 30 min) for RNA 
and protein isolation. Non-CMs in the supernatant were centrifuged 
at 500 g (10 min) and prepared for FACS. RBC in non-CMs were 
lysed and pellets resuspended in staining buffer (2% FBS/PBS, 2 mM 
EDTA, and 100 U/ml RNase inhibitor; catalog M0314L, New England 
BioLabs). Incubation with calcein AM (100 nM, room temperature, 
30 min) and then with CD45 and CD31 antibodies (catalogs 103114 
and 102508, BioLegend) on ice (30 min) was followed by 7-AAD (5 
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and LAH performed experiments. KIS performed and analyzed 
the PET studies. D. Scerbo and TL contributed to data analysis 
and discussion. KD, AEM, and KIS performed ISH and heart cell 
fractionation studies. NG edited the manuscript. KK assisted with 
Western blotting for insulin signaling analysis.
Acknowledgments
We thank Stephanie Chiang and Sunny Son for help with man-
uscript preparation and data analysis, Yun-ying Hu (New York 
University School of Medicine) for the kinetic studies, and Chyu-
an-Sheng Lin at the Columbia University Transgenic mouse 
Core for the generation of floxed mice by pronuclear DNA micro-
injection and embryo transfer. We thank the New York Universi-
ty Langone Medical Center OCS Microscopy Core, specifically 
Alice Liang, Kristen Dancel, and Yan Deng, for their consultation 
and assistance with transmission electron microscopic work. We 
also thank Nikki Fettig at the Radiological Chemistry and Imag-
ing Laboratory (RCIL) of the Mallinckrodt Institute of Radiology 
at Washington University for assistance with the [11C]palmitate 
and [18F]DG studies. We also thank A. Tall (Columbia Univer-
sity Medical Center), C. Semenkovich (Washington University 
School of Medicine), R. Kitsis (Department of Medicine, Albert 
Einstein College of Medicine, New York, New York, USA), and W. 
Blaner (Columbia University Medical Center) for constructive 
comments made during the preparation of this manuscript. The 
studies were funded by National Heart, Blood, and Lung Insti-
tute grants HL45095 and HL73029 (to IJG) and DK33301 and 
DK11175 (to NAA).
Address correspondence to: Ira J. Goldberg, Division of Endocri-
nology, Diabetes and Metabolism, NYU Langone Medical Cen-
ter, Science Building 617, 435 E. 30th Street, New York, New York 
10016, USA. Phone: 646.501.0589; Email: Ira.Goldberg@nyumc.
org. Or to: Nada A. Abumrad, Department of Medicine, Washing-
ton University School of Medicine, 660 S Euclid Avenue, Campus 
Box 8031, St. Louis, Missouri 63110, USA. Phone: 314.747.0348; 
Email: Nabumrad@wustl.edu.
with 100 μl PBS containing 1 × 106 dpm of [3H]oleic acid and 1 × 106 
of [14C]hexanoic acid (PerkinElmer). Mouse plasma volume was esti-
mated as 0.55 ml/kg BW (57). Plasma radioactive concentration was 
calculated by BW (mg) × (0.55 ml/1,000 mg) × 106 (dpm). Blood was 
collected 0, 30, 120, and 300 seconds after injection for radioactive 
counts (10 μl plasma). The heart vasculature was perfused with 10 
ml PBS via cardiac puncture 5 minutes after injection. Tissues were 
excised and accumulated radioactivity measured. Tissue oleic and 
hexanoic acid uptake was adjusted by plasma radioactivity at 30 min-
utes and normalized to that of  littermate controls.
PET studies. Differences in FA metabolism and FDG were evaluat-
ed with PET imaging of 4- to 5-month-old 16-hour–fasted mice using 
[11C]palmitate and [18F]DG as described previously (58). The uptake 
and transport of tracer were visualized and quantified by summing the 
uptake kinetics up to 60 minutes after tracer administration. All imag-
es and corresponding data were normalized to the dose and weight 
of the animal and presented as the standardized uptake value (SUV = 
activity × weight/injected dose).
Statistics. Results are expressed as the mean ± SD. Significant dif-
ferences between groups were determined by an ANOVA t test or a 
1-way ANOVA multiple comparisons test. The AUC value was evalu-
ated using the trapezoid method. A P value of less than 0.05 was con-
sidered significant.
Study approval. The IRBs of Columbia University and New York Uni-
versity Medical Center approved all study protocols. Generation of the 
mice and all metabolic and genetic studies were reviewed and approved 
by the IACUCs of New York University and Washington University.
Author contributions
NHS, NAA, and IJG designed the study and wrote the manuscript. 
NHS created the targeting constructs for the genetically modified 
mice and performed experiments assessing gene expression, plas-
ma metabolites, and tissue analysis. TAP assisted with construct 
design and validation of the mouse models. FW, XF, and SQY 
performed the radioactive FA uptake experiments. HRC created 
the LysM-Cre Cd36–/– mice and obtained data on their circulating 
lipid and glucose levels. D. Basu, D. Scerbo, TAP, STY, VSP, FS, SB, 
 1. Stern JH, Rutkowski JM, Scherer PE. Adiponec-
tin, leptin, and fatty acids in the maintenance of 
metabolic homeostasis through adipose tissue 
crosstalk. Cell Metab. 2016;23(5):770–784.
 2. Sorrentino D, Robinson RB, Kiang CL, Berk 
PD. At physiologic albumin/oleate concen-
trations oleate uptake by isolated hepato-
cytes, cardiac myocytes, and adipocytes is 
a saturable function of the unbound oleate 
concentration. Uptake kinetics are consistent 
with the conventional theory. J Clin Invest. 
1989;84(4):1325–1333.
 3. Murota K, Storch J. Uptake of micellar long-
chain fatty acid and sn-2-monoacylglycerol into 
human intestinal Caco-2 cells exhibits charac-
teristics of protein-mediated transport. J Nutr. 
2005;135(7):1626–1630.
 4. Abumrad NA, Goldberg IJ. CD36 actions in 
the heart: Lipids, calcium, inflammation, 
repair and more? Biochim Biophys Acta. 
2016;1861(10):1442–1449.
 5. Silverstein RL, Febbraio M. CD36, a scaven-
ger receptor involved in immunity, metabo-
lism, angiogenesis, and behavior. Sci Signal. 
2009;2(72):re3.
 6. Endemann G, Stanton LW, Madden KS, Bryant 
CM, White RT, Protter AA. CD36 is a receptor 
for oxidized low density lipoprotein. J Biol Chem. 
1993;268(16):11811–11816.
 7. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, 
Grimaldi PA. Cloning of a rat adipocyte membrane 
protein implicated in binding or transport of long-
chain fatty acids that is induced during preadipo-
cyte differentiation. Homology with human CD36. 
J Biol Chem. 1993;268(24):17665–17668.
 8. Hsieh FL, Turner L, Bolla JR, Robinson CV, 
Lavstsen T, Higgins MK. The structural basis for 
CD36 binding by the malaria parasite. Nat Com-
mun. 2016;7:12837.
 9. Nahlé Z, et al. CD36-dependent regulation of 
muscle FoxO1 and PDK4 in the PPAR delta/
beta-mediated adaptation to metabolic stress. 
 J Biol Chem. 2008;283(21):14317–14326.
 10. Samovski D, et al. Regulation of AMPK activation 
by CD36 links fatty acid uptake to β-oxidation. 
Diabetes. 2015;64(2):353–359.
 11. Coburn CT, Knapp FF, Febbraio M, Beets AL, Sil-
verstein RL, Abumrad NA. Defective uptake and 
utilization of long chain fatty acids in muscle and 
adipose tissues of CD36 knockout mice. J Biol 
Chem. 2000;275(42):32523–32529.
 12. Febbraio M, et al. A null mutation in murine 
CD36 reveals an important role in fatty acid 
and lipoprotein metabolism. J Biol Chem. 
1999;274(27):19055–19062.
 13. Drover VA, et al. CD36 deficiency impairs intestinal 
lipid secretion and clearance of chylomicrons from 
the blood. J Clin Invest. 2005;115(5):1290–1297.
 14. Nozaki S, et al. CD36 mediates long-chain fatty acid 
transport in human myocardium: complete myo-
cardial accumulation defect of radiolabeled long-
chain fatty acid analog in subjects with CD36 defi-
ciency. Mol Cell Biochem. 1999;192(1-2):129–135.
 15. Ma X, et al. A common haplotype at the CD36 
locus is associated with high free fatty acid levels 
and increased cardiovascular risk in Caucasians. 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 4 2 jci.org   Volume 128   Number 10   October 2018
Hum Mol Genet. 2004;13(19):2197–2205.
 16.  Wang Y, et al. Ephrin-B2 controls VEGF-induced 
angiogenesis and lymphangiogenesis. Nature. 
2010;465(7297):483–486.
 17. Hevener A, Reichart D, Janez A, Olefsky J. Female 
rats do not exhibit free fatty acid-induced insulin 
resistance. Diabetes. 2002;51(6):1907–1912.
 18. Priego T, Sánchez J, Picó C, Palou A. Sex-differ-
ential expression of metabolism-related genes in 
response to a high-fat diet. Obesity (Silver Spring). 
2008;16(4):819–826.
 19. Masuda D, et al. Chylomicron remnants are 
increased in the postprandial state in CD36 defi-
ciency. J Lipid Res. 2009;50(5):999–1011.
 20. Hajri T, Han XX, Bonen A, Abumrad NA. 
Defective fatty acid uptake modulates insu-
lin responsiveness and metabolic respons-
es to diet in CD36-null mice. J Clin Invest. 
2002;109(10):1381–1389.
 21. Lundsgaard AM, Kiens B. Gender differences in 
skeletal muscle substrate metabolism - molecular 
mechanisms and insulin sensitivity. Front Endo-
crinol (Lausanne). 2014;5:195.
 22. Fukuchi K, et al. Enhanced myocardial glucose 
use in patients with a deficiency in long-chain 
fatty acid transport (CD36 deficiency). J Nucl 
Med. 1999;40(2):239–243.
 23. Trent CM, et al. Lipoprotein lipase activity is 
required for cardiac lipid droplet production.  
J Lipid Res. 2014;55(4):645–658.
 24. Liu L, et al. Paradoxical coupling of triglyceride 
synthesis and fatty acid oxidation in skeletal 
muscle overexpressing DGAT1. Diabetes. 
2009;58(11):2516–2524.
 25. Monetti M, et al. Dissociation of hepatic steatosis 
and insulin resistance in mice overexpressing 
DGAT in the liver. Cell Metab. 2007;6(1):69–78.
 26. Ibrahimi A, et al. Muscle-specific overexpression 
of FAT/CD36 enhances fatty acid oxidation by 
contracting muscle, reduces plasma triglycerides 
and fatty acids, and increases plasma glucose and 
insulin. J Biol Chem. 1999;274(38):26761–26766.
 27. Nickerson JG, et al. Greater transport efficiencies 
of the membrane fatty acid transporters FAT/
CD36 and FATP4 compared with FABPpm and 
FATP1 and differential effects on fatty acid ester-
ification and oxidation in rat skeletal muscle.  
J Biol Chem. 2009;284(24):16522–16530.
 28. Coort SL, et al. Sulfo-N-succinimidyl esters of long 
chain fatty acids specifically inhibit fatty acid trans-
locase (FAT/CD36)-mediated cellular fatty acid 
uptake. Mol Cell Biochem. 2002;239(1-2):213–219.
 29. Jay AG, Chen AN, Paz MA, Hung JP, Hamilton 
JA. CD36 binds oxidized low density lipoprotein 
(LDL) in a mechanism dependent upon fatty acid 
binding. J Biol Chem. 2015;290(8):4590–4603.
 30. Bartelt A, et al. Brown adipose tissue activi-
ty controls triglyceride clearance. Nat Med. 
2011;17(2):200–205.
 31. Kanda T, et al. PPARgamma in the endothelium 
regulates metabolic responses to high-fat diet in 
mice. J Clin Invest. 2009;119(1):110–124.
 32. Coppiello G, et al. Meox2/Tcf15 heterodimers 
program the heart capillary endothelium 
for cardiac fatty acid uptake. Circulation. 
2015;131(9):815–826.
 33. Hagberg CE, et al. Targeting VEGF-B as a novel 
treatment for insulin resistance and type 2 diabe-
tes. Nature. 2012;490(7420):426–430.
 34. Kivelä R, et al. VEGF-B-induced vascular growth 
leads to metabolic reprogramming and isch-
emia resistance in the heart. EMBO Mol Med. 
2014;6(3):307–321.
 35. Jang C, et al. A branched-chain amino acid 
metabolite drives vascular fatty acid trans-
port and causes insulin resistance. Nat Med. 
2016;22(4):421–426.
 36. Salameh A, et al. Prohibitin/annexin 2 interaction 
regulates fatty acid transport in adipose tissue. 
JCI Insight. 2016;1(10):e86351.
 37. Nolan DJ, et al. Molecular signatures of tis-
sue-specific microvascular endothelial cell 
heterogeneity in organ maintenance and regen-
eration. Dev Cell. 2013;26(2):204–219.
 38. Glatz JF, Nabben M, Heather LC, Bonen A, 
Luiken JJ. Regulation of the subcellular traffick-
ing of CD36, a major determinant of cardiac 
fatty acid utilization. Biochim Biophys Acta. 
2016;1861(10):1461–1471.
 39. Angin Y, et al. CD36 inhibition prevents lipid 
accumulation and contractile dysfunction in rat 
cardiomyocytes. Biochem J. 2012;448(1):43–53.
 40. Sung MM, et al. Cardiomyocyte-specific 
ablation of CD36 accelerates the progression 
from compensated cardiac hypertrophy to 
heart failure. Am J Physiol Heart Circ Physiol. 
2017;312(3):H552–H560.
 41. Guerre-Millo M, et al. PPAR-alpha-null mice are 
protected from high-fat diet-induced insulin 
resistance. Diabetes. 2001;50(12):2809–2814.
 42. Kotani K, Peroni OD, Minokoshi Y, Boss O, Kahn 
BB. GLUT4 glucose transporter deficiency increas-
es hepatic lipid production and peripheral lipid 
utilization. J Clin Invest. 2004;114(11):1666–1675.
 43. Tordjman K, et al. PPARalpha deficiency reduces 
insulin resistance and atherosclerosis in apoE-
null mice. J Clin Invest. 2001;107(8):1025–1034.
 44. Augustus A, et al. Cardiac-specific knock-out 
of lipoprotein lipase alters plasma lipoprotein 
triglyceride metabolism and cardiac gene expres-
sion. J Biol Chem. 2004;279(24):25050–25057.
 45.  Samovski D, et al. Regulation of insulin receptor 
pathway and glucose metabolism by CD36 sig-
naling. Diabetes. 2018;67(7):1272–1284.
 46. Leprêtre F, et al. Genetic study of the CD36 gene 
in a French diabetic population. Diabetes Metab. 
2004;30(5):459–463.
 47. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, 
Yamashita S, Matsuzawa Y. CD36 deficiency 
associated with insulin resistance. Lancet. 
2001;357(9257):686–687.
 48. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, 
Dyck JR. Fatty acid translocase/CD36 deficiency 
does not energetically or functionally compro-
mise hearts before or after ischemia. Circulation. 
2004;109(12):1550–1557.
 49. Nagendran J, et al. Cardiomyocyte-specific abla-
tion of CD36 improves post-ischemic functional 
recovery. J Mol Cell Cardiol. 2013;63:180–188.
 50. Irie H, et al. Myocardial recovery from isch-
emia is impaired in CD36-null mice and 
restored by myocyte CD36 expression or medi-
um-chain fatty acids. Proc Natl Acad Sci USA. 
2003;100(11):6819–6824.
 51. Goldberg IJ, Trent CM, Schulze PC. Lipid 
metabolism and toxicity in the heart. Cell Metab. 
2012;15(6):805–812.
 52. Lopaschuk GD, Ussher JR, Folmes CD, Jas-
wal JS, Stanley WC. Myocardial fatty acid 
metabolism in health and disease. Physiol Rev. 
2010;90(1):207–258.
 53. Howard MD, Hood ED, Greineder CF, Alferiev IS, 
Chorny M, Muzykantov V. Targeting to endothelial 
cells augments the protective effect of novel dual 
bioactive antioxidant/anti-inflammatory nanopar-
ticles. Mol Pharm. 2014;11(7):2262–2270.
 54. Folch J, Lees M, Sloane Stanley GH. A simple 
method for the isolation and purification of 
total lipides from animal tissues. J Biol Chem. 
1957;226(1):497–509.
 55. Seo T, et al. Lipoprotein lipase-mediated selec-
tive uptake from low density lipoprotein requires 
cell surface proteoglycans and is independent 
of scavenger receptor class B type 1. J Biol Chem. 
2000;275(39):30355–30362.
 56. Louch WE, Sheehan KA, Wolska BM. Methods in 
cardiomyocyte isolation, culture, and gene trans-
fer. J Mol Cell Cardiol. 2011;51(3):288–298.
 57. Riches AC, Sharp JG, Thomas DB, Smith SV. 
Blood volume determination in the mouse.  
J Physiol (Lond). 1973;228(2):279–284.
 58. Burkart EM, et al. Nuclear receptors PPARbeta/
delta and PPARalpha direct distinct metabolic 
regulatory programs in the mouse heart. J Clin 
Invest. 2007;117(12):3930–3939.
